Research Article
The Influence of Depression and Anxiety on Neurological Disability in Multiple Sclerosis Patients
Table 2
Treatment details for studied patients.
| | Actual DMT | Number of patients (%), mean years of treatment | Number of patients with previous treatment (mean number of years) |
| | IFN-beta-1a i.m. | 46 (31.51), 2.5 | 6 (3.5) | | IFN-beta-1a s.c. | 21 (14.38), 3.0 | 6 (1.5) | | Glatiramer acetate | 45 (30.82), 4.9 | 2 (6) | | Natalizumab | 9 (6.16), 3.2 | 1 (1) | | IFN-beta-1b | 4 (2.74), 7.3 | 7 (5.4) | | Mitoxantrone | 2 (1.37), 1.5 | 0 | | Dimethyl fumarate | 1 (0.68), 9.0 | 0 | | No medication | 18 (12.33), 0.0 | 125 |
|
|
Abbreviations: IFN: interferon; i.m.: intramuscular; s.c.: subcutaneous.
|
